| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
First participant dosed in Phase 1 clinical trial of EQ504, proof-of-mechanism data expected in Q2 2027 |
| 26 Oct 2026 |
8-K: Unregistered Sales of Equity Securities; Regulation FD Disclosure +1 more
Topline Phase 1 proof-of-mechanism data anticipated in Q2 2027 |
| 05 Oct 2026 |
8-K: Other Events
On October 5, 2026, Equillium, Inc. (the Company) announced that the Company has received Human Research Ethics Committee approval and clearance from the Therapeutic Goods Administration in Australia under the Clinical Trial Notification... |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter |
| 29 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EQUILLIUM, INC. |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
Phase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected approximately six months thereafter |
| 25 Mar 2026 |
8-K: Results of Operations and Financial Condition
Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafter |
| 13 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 11, 2026, by and among Equillium, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an ... |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition
Closed financing of up to $50 million; initial tranche of $30 million provides runway through 2027 |
| 06 Oct 2025 |
8-K: Changes in Registrant's Certifying Accountant; Departure/Election of Directors or Officers; Compensation +1 more
We were previously principal accountants for Equillium, Inc. and, under the date of March 27, 2025, we reported on the consolidated financial statements of Equillium, Inc. as of and for the years ended December 31, 2024 and 2023. We were... |
| 19 Sep 2025 |
8-K: Other Events
We have acted as counsel to Equillium, Inc., a Delaware corporation (the “Company”), in connection with the offering by the Company of shares (the “Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”), having ag... |
| 04 Sep 2025 |
8-K: Other Events
On August 29, 2025, Equillium, Inc. (the "Company") received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with the minimum bid price r... |
| 11 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of August 10, 2025, by and among Equillium, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an... |
| 04 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
Equillium, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the... |
| 13 Jun 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
As previously disclosed, on December 13, 2024, Equillium, Inc. (the “Company”) received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the minimum b... |
| 22 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(a) Successor to and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the Equillium, Inc. 2017 Equity Incentive Plan (the “Prior Plan”). From and after 12:01 a.m. Pacific Time on the IPO Date, no a... |
| 24 Apr 2025 |
8-K: Results of Operations and Financial Condition
LA JOLLA, California, April 24, 2025 – Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disord... |
| 27 Mar 2025 |
8-K: Results of Operations and Financial Condition
Announced topline data from the Phase 3 EQUATOR study in first-line acute graft-versus-host disease |
| 06 Feb 2025 |
8-K: Other Events
On February 6, 2025, Equillium, Inc. (the “Company”) and Biocon Limited (“Biocon”) announced topline data from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ulcerative colitis (“UC”). |
| 13 Dec 2024 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
Loading...